< Back to search
Filter
1
Active & Responsive

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

for
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer,
Location: New York NY
Sponsor: Deborah Doroshow

Sex: All

Age: 18+

Code: NCT04997993

Phase1, Recruiting
Active & Responsive

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

for
Advanced Malignant Solid Neoplasm,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18+

Code: NCT06320405

Phase1, Phase2, Recruiting
Active & Responsive

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

for
Solid Tumor
Location: New York NY, Philadelphia PA, Washington D.C. DC,
Sponsor: Biohaven Therapeutics Ltd.

Sex: All

Age: 18+

Code: NCT06384807

Phase1, Phase2, Recruiting
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase1, Recruiting
Active & Responsive

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

for
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Location: Fairfax VA, Charleston SC, Detroit MI, Houston TX,
Sponsor: A2A Pharmaceuticals Inc.

Sex: All

Age: 18+

Code: NCT06136884

Phase1, Recruiting

Interested in new advanced solid tumor trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06066424

Phase1, Recruiting
Active & Responsive

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

for
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC),
Location: New York NY, East Brunswick NJ, Philadelphia PA,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07277413

Phase1, Recruiting
Active & Responsive

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

for
Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic,
Location: Hackensack NJ, Fairfax VA, Buffalo NY, Cleveland OH,
Sponsor: Whitehawk Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07444814

Phase1, Recruiting
Active & Responsive

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

for
Solid Tumor
Location: Portland OR
Sponsor: Axcynsis Therapeutics Pte Ltd

Sex: All

Age: 18+

Code: NCT06809114

Phase1, Recruiting
Active & Responsive

A Study of DM005 in Patients With Advanced Solid Tumors

for
Carcinoma, Non-Small-Cell Lung,
Location: Fairfax VA, Detroit MI, Dallas TX
Sponsor: Doma Biopharmaceutical（Suzhou）Co., Ltd.

Sex: All

Age: 18+

Code: NCT06515990

Phase1, Phase2, Recruiting
Active & Responsive

IKS014 in Advanced Solid Tumors That Express HER2

for
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Location: Boston MA, Nashville TN, Fort Worth TX,
Sponsor: Iksuda Therapeutics Ltd.

Sex: All

Age: 18+

Code: NCT05872295

Phase1, Recruiting
Active & Responsive

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

for
Advanced Solid Cancers
Location: New York NY, Orlando FL, Denver CO
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07186842

Phase1, Phase2, Recruiting
Active & Responsive

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

for
Solid Tumor Cancer
Location: Santa Monica CA
Sponsor: Sarcoma Oncology Research Center, LLC

Sex: All

Age: 18+

Code: NCT07671534

Phase2, Recruiting
Active & Responsive

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

for
Metastatic Castration Resistant Prostate Cancer, mCRPC,
Location: East Brunswick NJ, Fairfax VA, Myrtle Beach SC,
Sponsor: Flare Therapeutics Inc.

Sex: Male

Age: 18+

Code: NCT07719361

Phase1, Recruiting
Active & Responsive

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

for
Metastatic Solid Tumors, Stage 4 Cancer
Location: Rochester MN
Sponsor: New Phase Ltd.

Sex: All

Age: 18+

Code: NCT07224464

Recruiting
Active & Responsive

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

for
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy),
Location: Stony Brook NY, New York NY, Montreal, Baltimore MD,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06535607

Phase2, Recruiting
Active & Responsive

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

for
Prostate Cancer Castration-resistant Prostate Cancer,
Location: East Brunswick NJ, Fairfax VA, Grand Rapids MI,
Sponsor: MBrace Therapeutics

Sex: All

Age: 18+

Code: NCT07145255

Phase1, Phase2, Recruiting
Active & Responsive

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

for
Solid Tumor
Location: Canton OH, Cleveland OH
Sponsor: Lamassu Bio Inc

Sex: All

Age: 18+

Code: NCT06578624

Phase1, Phase2, Recruiting
Active & Responsive

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

for
Metastatic Hepatocellular Carcinoma,
Location: New York NY, Pittsburgh PA, Nashville TN, Zion IL,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06427941

Phase1, Phase2, Recruiting
Active & Responsive

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

for
Solid Tumors (Phase 1), RAS Mutation
Location: Orlando FL, Houston TX
Sponsor: Adlai Nortye Biopharma Co., Ltd.

Sex: All

Age: 18+

Code: NCT07252479

Phase1, Recruiting